Ballal Rahul D.
SEC CIK 1805097 · EDGAR
BoughtSold
Most active insiders at AGIO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Goff Brian | CEO, Dir | — | $1.69M |
| 2 | Gheuens Sarah | Chief Medical Off | — | $1.63M |
| 3 | Jones Cecilia | CFO | — | $468.5K |
| 4 | Milanova Tsveta | Chief Commercial Off | — | $353.3K |
| 5 | Burns James William | CLO | — | $344.4K |
| 6 | Washburn Theodore James Jr. | Principal Accounting Off | — | $216.6K |
| 7 | Viswanadhan Krishnan | Chief Corp Dev, Strategy | — | $185.0K |
| 8 | Scadden David | Dir | — | $25.0K |
| 9 | Owen Adams Catherine | Dir | — | — |
| 10 | Ballal Rahul D. | Dir | — | — |
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-23 17:25 | 2026-06-18 | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | M - OptEx | $0.00 | +2,816 | 15.2K | +23% | $0 |
| D | 2025-08-13 | 2025-08-11 | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | M - OptEx | $0.00 | +2,302 | 12.4K | +23% | $0 |
| D | 2025-06-23 | 2025-06-20 | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | M - OptEx | $0.00 | +2,120 | 10.1K | +27% | $0 |
| DM | 2024-11-12 | 2024-11-07+ | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | S - Sale+OE | $55.86 | -20.0K | 7,992 | -71% | -$1.12M |
| DM | 2024-11-12 | 2024-11-07+ | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | M - OptEx | $25.99 | +20.0K | 18.0K | New | +$519.8K |
| DM | 2024-10-10 | 2024-10-08 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | M - OptEx | $14.10 | +10.4K | 32.8K | +47% | +$146.9K |
| D | 2024-10-10 | 2024-10-08 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $28.17 | -10.4K | 22.3K | -32% | -$293.5K |
| D | 2024-08-13 | 2024-08-11 | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | M - OptEx | $0.00 | +2,302 | 7,992 | +40% | $0 |
| D | 2024-06-17 | 2024-06-13 | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | M - OptEx | $0.00 | +3,388 | 5,690 | +147% | $0 |
| DM | 2024-04-12 | 2024-04-10+ | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | M - OptEx | $13.08 | +67.0K | 75.7K | +767% | +$876.6K |
| DM | 2024-04-12 | 2024-04-10+ | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $23.36 | -67.0K | 45.4K | -60% | -$1.57M |
| D | 2024-04-08 | 2024-04-04 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $19.15 | -3,485 | 22.3K | -13% | -$66.7K |
| D | 2024-04-08 | 2024-04-04 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | M - OptEx | $12.60 | +3,485 | 25.8K | +16% | +$43.9K |
| DM | 2024-04-03 | 2024-04-01 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | M - OptEx | $5.73 | +3,237 | 25.6K | +14% | +$18.5K |
| D | 2024-04-03 | 2024-04-01 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $19.08 | -3,237 | 22.3K | -13% | -$61.8K |
| D | 2024-03-22 | 2024-03-20 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | M - OptEx | $5.52 | +13.3K | 35.6K | +59% | +$73.3K |
| D | 2024-03-22 | 2024-03-20 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $19.16 | -13.3K | 22.3K | -37% | -$254.4K |
| D | 2023-08-15 | 2023-08-11 | AGIO | AGIOS PHARMACEUTICALS, INC. | Ballal Rahul D. | Dir | M - OptEx | $0.00 | +2,302 | 2,302 | New | $0 |
| 2023-02-22 | 2023-02-22 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | CEO | S - Sale | $4.66 | -32.9K | 87.8K | -27% | -$153.1K | |
| 2023-02-01 | 2023-01-30 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | CEO | S - Sale | $3.91 | -11.3K | 120.7K | -9% | -$44.2K | |
| D | 2022-02-01 | 2022-01-28 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | CEO | A - Grant | $0.00 | +131.4K | 137.0K | +2,343% | $0 |
Purchase Sale Sale after option exercise All abbreviations